DIABETIC GASTROPARESIS TREATMENT MARKET ANALYSIS

Diabetic Gastroparesis Treatment Market, By Product Type (Drugs (Gastroprokinetic Agents, Antiemetic Agents, Botulinum Toxin), Surgical Treatment Products (Gastric Electrical Stimulation (GES) Device, Percutaneous Endoscopic Gastrostomy (PEG) Kit, Parenteral Nutrition)), By Disease Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : May 2023
Code : CMI3603
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Diabetic Gastroparesis Treatment Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global diabetic gastroparesis treatment market over the forecast period. This is due to the increasing aging population and the rising number of surgical procedures. The U.S. dominated the market owing to a large prediabetic population, favorable reimbursement policies, and more awareness about the condition. For instance, according to the data from Centers for Drug Control and Prevention in June 2022, 96 million people aged 18 years or older have prediabetes (38.0% of the adult U.S. population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also responsible for the dominance of the region in the market. Thus, the rise in diabetes cases is anticipated to increase market growth over the forecast period.

North America: U.S. and Canada

Latin America: Brazil, Argentina, Mexico, and Rest of Latin America

Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe

Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific

Middle East: GCC Countries, Israel, and Rest of Middle East

Africa: South Africa, North Africa, and Central Africa